Merck & Co., Inc. (MRK) 10-Year Financial Performance & Capital Metrics

MRK • • Industrial / General

HealthcareLarge PharmaBroad-Based Pharmaceutical GiantsGlobal Pharma Diversified Leaders

AboutMerck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.Show more

Revenue $64.17B +6.7%
EBITDA $24.72B +262.1%
Net Income $17.12B +4589.6%
EPS (Diluted) 6.74 +4714.3%
Gross Margin 76.32% +4.3%
EBITDA Margin 38.52% +239.3%
Operating Margin 31.51% +541.3%
Net Margin 26.68% +4293.2%
ROE 40.75% +4572.3%
ROIC 21.91% +554.6%
Debt/Equity 0.83 -14.4%
Interest Coverage 15.91 +517.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 25.4%
✓Strong Piotroski F-Score: 8/9
✓FCF machine: 28.2% free cash flow margin
✓13 consecutive years of dividend growth
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 10.4%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y4.27%

5Y10.4%

3Y9.63%

TTM1.68%

Profit (Net Income) CAGR

10Y3.68%

5Y11.7%

3Y9.47%

TTM56.68%

EPS CAGR

10Y5.17%

5Y12.03%

3Y9.45%

TTM58.7%

ROCE

10Y Avg12.82%

5Y Avg15.23%

3Y Avg16.44%

Latest23.84%

Peer Comparison

Global Pharma Diversified Leaders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AZNAstraZeneca PLC	293.03B	94.51	83.64	18.04%	16.17%	20.45%	2.48%	0.74
GSKGSK plc	100.65B	49.90	40.24	3.46%	17.08%	25.91%	3.55%	1.30
JNJJohnson & Johnson	514.75B	213.65	36.90	4.3%	27.26%	31.69%	3.85%	0.53
NVSNovartis AG	271.72B	141.61	24.12	10.85%	25.53%	32.16%	5.08%	0.71
SNYSanofi	114.36B	47.20	21.55	6.41%	21.16%	12.99%	5.15%	0.23
PFEPfizer Inc.	143B	25.15	17.84	6.84%	15.64%	10.55%	6.88%	0.76
MRKMerck & Co., Inc.	268.7B	108.26	16.06	6.74%	29.63%	36.67%	6.73%	0.83

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	39.5B	39.81B	40.12B	42.29B	39.12B	41.52B	48.7B	59.28B	60.12B	64.17B
Revenue Growth %	-0.06%	0.01%	0.01%	0.05%	-0.08%	0.06%	0.17%	0.22%	0.01%	0.07%
Cost of Goods Sold+	14.93B	14.03B	12.91B	13.51B	12.02B	13.62B	13.63B	17.41B	16.13B	15.19B
COGS % of Revenue	0.38%	0.35%	0.32%	0.32%	0.31%	0.33%	0.28%	0.29%	0.27%	0.24%
Gross Profit+	24.56B	25.78B	27.21B	28.79B	27.11B	27.9B	35.08B	41.87B	43.99B	48.98B
Gross Margin %	0.62%	0.65%	0.68%	0.68%	0.69%	0.67%	0.72%	0.71%	0.73%	0.76%
Gross Profit Growth %	-0.04%	0.05%	0.06%	0.06%	-0.06%	0.03%	0.26%	0.19%	0.05%	0.11%
Operating Expenses+	17.02B	20.28B	20.41B	19.85B	19.18B	22.35B	21.88B	23.59B	41.03B	28.75B
OpEx % of Revenue	0.43%	0.51%	0.51%	0.47%	0.49%	0.54%	0.45%	0.4%	0.68%	0.45%
Selling, General & Admin	10.31B	10.02B	10.07B	10.1B	9.46B	8.57B	9.4B	9.67B	9.88B	10.1B
SG&A % of Revenue	0.26%	0.25%	0.25%	0.24%	0.24%	0.21%	0.19%	0.16%	0.16%	0.16%
Research & Development	6.7B	10.26B	10.34B	9.75B	9.72B	13.4B	12.24B	13.55B	30.53B	17.94B
R&D % of Revenue	0.17%	0.26%	0.26%	0.23%	0.25%	0.32%	0.25%	0.23%	0.51%	0.28%
Other Operating Expenses	0	0	0	0	0	386M	231M	373M	620M	716M
Operating Income+	7.55B	5.5B	6.8B	8.93B	7.93B	5.55B	13.2B	18.28B	2.95B	20.22B
Operating Margin %	0.19%	0.14%	0.17%	0.21%	0.2%	0.13%	0.27%	0.31%	0.05%	0.32%
Operating Income Growth %	0.13%	-0.27%	0.24%	0.31%	-0.11%	-0.3%	1.38%	0.39%	-0.84%	5.85%
EBITDA+	13.92B	10.97B	11.47B	13.45B	11.24B	9.03B	16.41B	22.19B	6.83B	24.72B
EBITDA Margin %	0.35%	0.28%	0.29%	0.32%	0.29%	0.22%	0.34%	0.37%	0.11%	0.39%
EBITDA Growth %	0.04%	-0.21%	0.05%	0.17%	-0.16%	-0.2%	0.82%	0.35%	-0.69%	2.62%
D&A (Non-Cash Add-back)	6.38B	5.47B	4.68B	4.52B	3.31B	3.49B	3.21B	3.91B	3.87B	4.5B
EBIT	6.07B	5.35B	7.28B	9.47B	8.06B	6.69B	14.69B	17.41B	3.04B	21.21B
Net Interest Income+	-383M	-365M	-369M	-429M	-619M	-772M	-770M	-805M	-781M	-856M
Interest Income	289M	328M	385M	343M	274M	59M	36M	157M	365M	415M
Interest Expense	672M	693M	754M	772M	893M	831M	806M	962M	1.15B	1.27B
Other Income/Expense	-2.15B	-840M	-276M	-230M	-755M	315M	680M	-1.84B	-1.06B	-285M
Pretax Income+	5.4B	4.66B	6.52B	8.7B	7.17B	5.86B	13.88B	16.44B	1.89B	19.94B
Pretax Margin %	0.14%	0.12%	0.16%	0.21%	0.18%	0.14%	0.28%	0.28%	0.03%	0.31%
Income Tax+	942M	718M	4.1B	2.51B	1.56B	1.34B	1.52B	1.92B	1.51B	2.8B
Effective Tax Rate %	0.82%	0.84%	0.37%	0.71%	1.37%	1.21%	0.94%	0.88%	0.19%	0.86%
Net Income+	4.44B	3.92B	2.39B	6.22B	9.84B	7.07B	13.05B	14.52B	365M	17.12B
Net Margin %	0.11%	0.1%	0.06%	0.15%	0.25%	0.17%	0.27%	0.24%	0.01%	0.27%
Net Income Growth %	-0.63%	-0.12%	-0.39%	1.6%	0.58%	-0.28%	0.85%	0.11%	-0.97%	45.9%
Net Income (Continuing)	4.46B	3.94B	2.42B	6.19B	5.61B	4.52B	12.36B	14.53B	377M	17.13B
Discontinued Operations	0	0	0	0	4.15B	2.55B	704M	0	0	0
Minority Interest	91M	220M	233M	181M	94M	87M	73M	67M	54M	59M
EPS (Diluted)+	1.56	2.04	0.93	2.32	3.82	2.78	5.14	5.71	0.14	6.74
EPS Growth %	-0.62%	0.31%	-0.54%	1.49%	0.65%	-0.27%	0.85%	0.11%	-0.98%	47.14%
EPS (Basic)	1.60	2.07	0.95	2.40	3.84	2.79	5.16	5.73	0.14	6.76
Diluted Shares Outstanding	2.84B	2.79B	2.75B	2.68B	2.58B	2.54B	2.54B	2.54B	2.55B	2.54B
Basic Shares Outstanding	2.78B	2.75B	2.7B	2.59B	2.56B	2.53B	2.53B	2.53B	2.61B	2.53B
Dividend Payout Ratio	1.15%	1.31%	2.16%	0.83%	0.58%	0.88%	0.51%	0.48%	20.4%	0.46%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	29.75B	30.61B	24.77B	25.88B	27.48B	27.76B	30.27B	35.72B	32.17B	38.78B
Cash & Short-Term Investments	13.43B	14.34B	8.5B	8.86B	10.45B	8.05B	8.1B	13.19B	7.09B	13.69B
Cash Only	8.52B	6.51B	6.09B	7.96B	9.68B	8.05B	8.1B	12.69B	6.84B	13.24B
Short-Term Investments	4.9B	7.83B	2.41B	899M	774M	0	0	498M	252M	447M
Accounts Receivable	6.48B	7.02B	6.87B	7.07B	6.78B	6.8B	9.23B	9.45B	10.35B	10.28B
Days Sales Outstanding	59.92	64.35	62.53	61.02	63.24	59.81	69.17	58.18	62.84	58.46
Inventory	4.7B	4.87B	5.1B	5.44B	5.98B	5.55B	5.95B	5.91B	6.36B	6.11B
Days Inventory Outstanding	114.87	126.59	144.06	146.98	181.59	148.86	159.46	123.92	143.91	146.76
Other Current Assets	5.14B	4.39B	4.3B	4.5B	4.28B	7.36B	6.99B	7.17B	8.37B	8.71B
Total Non-Current Assets+	71.93B	64.76B	63.11B	56.76B	56.91B	63.82B	75.43B	73.44B	74.51B	78.32B
Property, Plant & Equipment	12.51B	12.03B	12.44B	13.29B	15.05B	17B	19.28B	21.42B	23.05B	23.78B
Fixed Asset Turnover	3.16x	3.31x	3.23x	3.18x	2.60x	2.44x	2.53x	2.77x	2.61x	2.70x
Goodwill	17.72B	18.16B	18.28B	18.25B	19.43B	18.88B	21.26B	21.2B	21.2B	21.67B
Intangible Assets	22.6B	17.3B	14.18B	13.1B	14.2B	14.1B	22.93B	20.27B	18.01B	16.37B
Long-Term Investments	13.04B	11.42B	12.13B	6.23B	1.47B	785M	370M	1.01B	252M	463M
Other Non-Current Assets	6.05B	5.85B	6.08B	5.88B	6.77B	13.06B	11.58B	9.53B	12B	16.04B
Total Assets+	101.68B	95.38B	87.87B	82.64B	84.4B	91.59B	105.69B	109.16B	106.67B	117.11B
Asset Turnover	0.39x	0.42x	0.46x	0.51x	0.46x	0.45x	0.46x	0.54x	0.56x	0.55x
Asset Growth %	0.04%	-0.06%	-0.08%	-0.06%	0.02%	0.09%	0.15%	0.03%	-0.02%	0.1%
Total Current Liabilities+	19.2B	17.2B	18.61B	22.21B	22.22B	27.33B	23.87B	24.24B	25.69B	28.42B
Accounts Payable	2.53B	2.81B	3.1B	3.32B	3.74B	4.33B	4.61B	4.26B	3.92B	4.08B
Days Payables Outstanding	61.91	73.03	87.69	89.65	113.55	115.98	123.46	89.39	88.77	97.99
Short-Term Debt	2.58B	568M	3.06B	5.31B	3.61B	6.43B	2.41B	1.95B	1.37B	2.65B
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	0	0	795M	-304M	-281M	-285M	-282M
Current Ratio	1.55x	1.78x	1.33x	1.17x	1.24x	1.02x	1.27x	1.47x	1.25x	1.36x
Quick Ratio	1.30x	1.50x	1.06x	0.92x	0.97x	0.81x	1.02x	1.23x	1.00x	1.15x
Cash Conversion Cycle	112.88	117.92	118.89	118.36	131.28	92.69	105.17	92.71	117.97	107.23
Total Non-Current Liabilities+	37.71B	37.87B	34.69B	33.55B	36.18B	38.86B	43.56B	38.86B	43.35B	42.31B
Long-Term Debt	23.83B	24.27B	21.35B	19.81B	22.74B	25.36B	30.69B	28.75B	33.68B	34.46B
Capital Lease Obligations	0	0	0	0	768M	1.33B	1.23B	1.01B	928M	877M
Deferred Tax Liabilities	6.54B	5.08B	2.22B	1.7B	1.47B	1B	3.44B	1.79B	871M	1.39B
Other Non-Current Liabilities	7.34B	8.51B	11.12B	12.04B	11.2B	11.16B	8.21B	7.31B	7.86B	5.59B
Total Liabilities	56.91B	55.07B	53.3B	55.76B	58.4B	66.18B	67.44B	63.1B	69.04B	70.73B
Total Debt+	26.41B	24.84B	24.41B	25.11B	27.35B	33.42B	34.63B	31.98B	36.27B	38.27B
Net Debt	17.89B	18.33B	18.32B	17.15B	17.68B	25.37B	26.54B	19.29B	29.43B	25.03B
Debt / Equity	0.59x	0.62x	0.71x	0.93x	1.05x	1.32x	0.91x	0.69x	0.96x	0.83x
Debt / EBITDA	1.90x	2.26x	2.13x	1.87x	2.43x	3.70x	2.11x	1.44x	5.31x	1.55x
Net Debt / EBITDA	1.28x	1.67x	1.60x	1.28x	1.57x	2.81x	1.62x	0.87x	4.31x	1.01x
Interest Coverage	11.23x	7.94x	9.01x	11.57x	8.88x	6.68x	16.38x	19.00x	2.58x	15.91x
Total Equity+	44.77B	40.31B	34.57B	26.88B	26B	25.4B	38.26B	46.06B	37.63B	46.37B
Equity Growth %	-0.08%	-0.1%	-0.14%	-0.22%	-0.03%	-0.02%	0.51%	0.2%	-0.18%	0.23%
Book Value per Share	15.76	14.46	12.58	10.03	10.08	10.00	15.07	18.12	14.78	18.25
Total Shareholders' Equity	44.68B	40.09B	34.34B	26.7B	25.91B	25.32B	38.18B	45.99B	37.58B	46.31B
Common Stock	1.79B	1.79B	1.79B	1.79B	1.79B	1.79B	1.79B	1.79B	1.79B	1.79B
Retained Earnings	45.35B	44.13B	41.35B	42.58B	46.6B	47.36B	53.7B	61.08B	53.9B	63.07B
Treasury Stock	-38.53B	-40.55B	-43.79B	-50.93B	-55.95B	-56.79B	-57.11B	-56.49B	-57.45B	-58.3B
Accumulated OCI	-4.15B	-5.23B	-4.91B	-5.54B	-6.19B	-6.63B	-4.43B	-4.77B	-5.16B	-4.95B
Minority Interest	91M	220M	233M	181M	94M	87M	73M	67M	54M	59M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	12.42B	10.38B	6.45B	10.92B	13.44B	10.25B	14.11B	19.09B	13.01B	21.47B
Operating CF Margin %	0.31%	0.26%	0.16%	0.26%	0.34%	0.25%	0.29%	0.32%	0.22%	0.33%
Operating CF Growth %	0.58%	-0.16%	-0.38%	0.69%	0.23%	-0.24%	0.38%	0.35%	-0.32%	0.65%
Net Income	4.46B	3.94B	2.42B	6.19B	9.78B	7.08B	12.36B	14.53B	365M	17.13B
Depreciation & Amortization	6.38B	5.44B	4.64B	4.52B	3.65B	3.63B	3.21B	3.91B	3.87B	4.5B
Stock-Based Compensation	299M	300M	312M	348M	417M	441M	479M	541M	645M	761M
Deferred Taxes	-764M	-1.52B	-2.62B	-509M	-556M	-668M	187M	-1.57B	-1.9B	-1.25B
Other Non-Cash Items	2.32B	4.82B	6.72B	1.92B	2.22B	4.36B	1.71B	4.47B	12.23B	3.99B
Working Capital Changes	-268M	-2.6B	-5.02B	-1.55B	-2.07B	-4.59B	-3.84B	-2.78B	-2.21B	-3.67B
Change in Receivables	-480M	-619M	297M	-418M	294M	-1B	-2.03B	-644M	-1.15B	-244M
Change in Inventory	805M	206M	-145M	-911M	-508M	-855M	-674M	-161M	-816M	-835M
Change in Payables	-37M	278M	254M	230M	399M	724M	405M	-289M	-380M	182M
Cash from Investing+	-4.76B	-3.21B	2.68B	4.31B	-2.63B	-9.44B	-16.55B	-4.96B	-14.08B	-7.73B
Capital Expenditures	-1.28B	-1.61B	-1.89B	-2.62B	-3.47B	-4.68B	-4.45B	-4.39B	-3.86B	-3.37B
CapEx % of Revenue	0.03%	0.04%	0.05%	0.06%	0.09%	0.11%	0.09%	0.07%	0.06%	0.05%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	221M	482M	38M	102M	378M	130M	-225M	32M	1.11B	-127M
Cash from Financing+	-5.39B	-9.04B	-10.01B	-13.16B	-8.86B	-2.83B	2.59B	-9.12B	-4.81B	-7.03B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-5.12B	-5.12B	-5.17B	-5.17B	-5.7B	-6.21B	-6.61B	-7.01B	-7.45B	-7.84B
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	424M	821M	304M	266M	366M	-347M	8.41B	-240M	-203M	-195M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	11.14B	8.76B	4.56B	8.31B	9.97B	5.57B	9.66B	14.71B	9.14B	18.1B
FCF Margin %	0.28%	0.22%	0.11%	0.2%	0.25%	0.13%	0.2%	0.25%	0.15%	0.28%
FCF Growth %	1.01%	-0.21%	-0.48%	0.82%	0.2%	-0.44%	0.73%	0.52%	-0.38%	0.98%
FCF per Share	3.92	3.14	1.66	3.10	3.86	2.19	3.81	5.79	3.59	7.12
FCF Conversion (FCF/Net Income)	2.80x	2.65x	2.69x	1.76x	1.37x	1.45x	1.08x	1.32x	35.63x	1.25x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	9.5%	9.22%	6.39%	20.24%	37.23%	27.5%	41%	34.44%	0.87%	40.75%
Return on Invested Capital (ROIC)	9.03%	6.8%	9.14%	13.82%	13.56%	8.81%	17.13%	21.07%	3.35%	21.91%
Gross Margin	62.19%	64.75%	67.82%	68.06%	69.28%	67.2%	72.02%	70.63%	73.17%	76.32%
Net Margin	11.25%	9.85%	5.97%	14.71%	25.16%	17.02%	26.79%	24.49%	0.61%	26.68%
Debt / Equity	0.59x	0.62x	0.71x	0.93x	1.05x	1.32x	0.91x	0.69x	0.96x	0.83x
Interest Coverage	11.23x	7.94x	9.01x	11.57x	8.88x	6.68x	16.38x	19.00x	2.58x	15.91x
FCF Conversion	2.80x	2.65x	2.69x	1.76x	1.37x	1.45x	1.08x	1.32x	35.63x	1.25x
Revenue Growth	-6.48%	0.78%	0.79%	5.41%	-7.5%	6.13%	17.31%	21.72%	1.4%	6.74%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Pharmaceutical segment	34.78B	35.15B	35.39B	37.69B	41.75B	43.02B	42.75B	52.01B	53.58B	57.4B
Pharmaceutical segment Growth	-	1.06%	0.68%	6.50%	10.78%	3.04%	-0.62%	21.64%	3.03%	7.12%
Animal Health segment	-	-	-	4.21B	4.39B	4.7B	5.57B	5.55B	5.63B	5.88B
Animal Health segment Growth	-	-	-	-	4.30%	7.06%	18.39%	-0.32%	1.35%	4.48%
Others	4.72B	4.66B	4.73B	393M	696M	23M	382M	1.73B	907M	891M
Others Growth	-	-1.27%	1.63%	-91.69%	77.10%	-96.70%	1560.87%	352.36%	-47.51%	-1.76%

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	17.52B	18.48B	17.42B	18.21B	20.32B	21.03B	22.43B	27.21B	-	32.28B
UNITED STATES Growth	-	5.47%	-5.70%	4.52%	11.60%	3.45%	6.65%	21.32%	-	-
EMEA	10.68B	10.95B	11.48B	12.21B	12.71B	13.6B	13.34B	14.49B	-	14.04B
EMEA Growth	-	2.58%	4.79%	6.40%	4.04%	7.03%	-1.90%	8.64%	-	-
CHINA	-	-	-	2.18B	3.21B	3.62B	4.38B	5.19B	-	5.49B
CHINA Growth	-	-	-	-	46.84%	13.00%	20.81%	18.57%	-	-
Latin America	2.82B	2.15B	2.34B	2.42B	2.47B	2.27B	2.21B	2.58B	-	3.46B
Latin America Growth	-	-23.66%	8.54%	3.25%	2.24%	-7.90%	-2.99%	17.04%	-	-
JAPAN	2.67B	2.85B	3.12B	3.21B	3.58B	3.38B	2.73B	3.63B	-	3.28B
JAPAN Growth	-	6.47%	9.70%	2.88%	11.55%	-5.78%	-19.25%	33.13%	-	-
Asia Pacific	3.82B	3.92B	4.34B	2.91B	2.94B	2.86B	2.41B	3.61B	-	3.06B
Asia Pacific Growth	-	2.57%	10.69%	-32.93%	1.17%	-2.68%	-15.96%	50.15%	-	-
International	1.99B	1.46B	1.42B	1.15B	1.61B	1.23B	1.22B	2.57B	-	2.56B
International Growth	-	-26.64%	-2.40%	-19.20%	39.77%	-23.47%	-0.65%	110.32%	-	-
Pharmaceutical segment	-	-	-	-	-	-	-	-	53.58B	-
Pharmaceutical segment Growth	-	-	-	-	-	-	-	-	-	-
Animal Health segment	-	-	-	-	-	-	-	-	5.63B	-
Animal Health segment Growth	-	-	-	-	-	-	-	-	-	-
Others	-	-	-	-	-	-	-	-	907M	-
Others Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Merck & Co., Inc. (MRK) has a price-to-earnings (P/E) ratio of 16.1x. This is roughly in line with market averages.

Growth & Financials

Merck & Co., Inc. (MRK) reported $64.23B in revenue for fiscal year 2024. This represents a 34% increase from $48.05B in 2011.

Merck & Co., Inc. (MRK) grew revenue by 6.7% over the past year. This is steady growth.

Yes, Merck & Co., Inc. (MRK) is profitable, generating $19.03B in net income for fiscal year 2024 (26.7% net margin).

Dividend & Returns

Yes, Merck & Co., Inc. (MRK) pays a dividend with a yield of 2.85%. This makes it attractive for income-focused investors.

Merck & Co., Inc. (MRK) has a return on equity (ROE) of 40.8%. This is excellent, indicating efficient use of shareholder capital.

Merck & Co., Inc. (MRK) generated $13.05B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...